MeCo Score™

Report Date: MM/DD/YYYY

Patient:	Sample Patient	Ordering Client:	
Sex at Birth:	Female	Specimen Type:	FFPE Block
DOB:	MM/DD/YYYY	Specimen Site:	Breast
Medical Record #:		Tumor Collection Date:	MM/DD/YYYY
Client Accession #:		Received Date:	MM/DD/YYYY
Ordering Physician:	Sample Physician		

RESULTS SNAPSHOT

Platform: Illumina NovaSeq 6000Dx whole transcriptome RNA sequencing

Actionable results: Yes

Level of Evidence: NCCN Category TBD

Diagnosis: Invasive breast carcinoma; pT2, pN0, M0
[ER (POSITIVE); PgR (POSITIVE); HER2 (NEGATIVE); Ki-67 (11%)]

KEY BIOMARKER FINDING

KEY BIOMARKER	FDA-APPROVED DRUGS for patient's disease	FDA-APPROVED DRUGS for another disease[1]	COST-EFFECTIVE GENERIC DRUG EMERGENT	DRUGS PREDICTED NON-BENEFICIAL/ REDUCED BENEFIT[2]
High MeCo Score: 87/100		Nintedanib	Yes*	Pembrolizumab

~5X increase in event-free survival likelihood at 5 years post-therapy (relative)



PMID: 39283720

DOI: 10.1158/1078-0432.CCR-24-1518

CLINICAL SIGNIFICANCE

High MeCo Score patients with early-stage HER2-negative breast cancer who received nintedanib + chemotherapy vs. chemotherapy alone (control) experienced a significant reduction in risk of recurrence for over 10 years after therapy

[1]The prescribing information for the FDA-approved therapy option may not include the associated Key Biomarker.

[2]Data sourced from I-SPY 2 neoadjuvant trial platform and on file at MeCo Diagnostics.

*Projected for European market entry in 2025 and US market entry in 2026.

EFS: the length of time after primary treatment that a patient remains free of complications or events that the treatment was intended to prevent or delay.